Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

254
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
254
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

195
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
195
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

500
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
500
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

448
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
448
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

246
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
246

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Worldwide evaluation of Clinical Practice Strategies (CliPS) for lung involvement in Still's disease within the JIR-CliPS network: a COST action.

Rheumatology advances in practice·2025
Same author

Gastrointestinal and Intra-Abdominal Mucormycosis in Non-Haematological Patients-A Comprehensive Review.

Journal of fungi (Basel, Switzerland)·2025
Same author

[New developments in juvenile arthritis].

Revue medicale suisse·2025
Same author

Inflammatory Choroidal Neovascularization in Pediatric Uveitis: A Case Series.

Klinische Monatsblatter fur Augenheilkunde·2025
Same author

Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort.

Pediatric rheumatology online journal·2023
Same author

Phenotypic Characterization of Timothy Syndrome Caused by the <i>CACNA1C</i> p.Gly402Ser Variant.

Circulation. Genomic and precision medicine·2023

Video Experimental Relacionado

Updated: Jan 18, 2026

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
12:18

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA

Published on: February 9, 2011

23.6K

Pediatría. Enfermedad de Kawasaki

Sabrina Bressieux-Degueldre1, Katerina Theodoropoulou2, Alain Lefèvre-Utile3

  • 1Unité de cardiologie pédiatrique, Service de pédiatrie, Département femme-mère-enfant, Centre hospitalier universitaire vaudois, 1011 Lausanne.

Revue medicale suisse
|January 16, 2026
PubMed
Resumen

La enfermedad de Kawasaki, una vasculitis aguda en niños pequeños, puede provocar problemas en las arterias coronarias si no se trata. Las guías actualizadas ayudan al diagnóstico y tratamiento tempranos, mejorando los resultados para los niños afectados.

Palabras clave:
enfermedad de Kawasakivasculitis pediátricaarterias coronariasguías de práctica clínicaSuiza

Más Videos Relacionados

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.4K
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

15.4K

Videos de Experimentos Relacionados

Last Updated: Jan 18, 2026

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
12:18

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA

Published on: February 9, 2011

23.6K
A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.4K
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

15.4K

Área de la Ciencia:

  • Pediatría; Reumatología; Cardiología

Sus antecedentes:

  • La enfermedad de Kawasaki es una causa principal de cardiopatía adquirida en niños.
  • La enfermedad de Kawasaki no tratada conlleva un riesgo significativo (25%) de aneurismas de las arterias coronarias.
  • Las actualizaciones recientes de las guías en Europa y América del Norte impactan las estrategias de diagnóstico y tratamiento.

Objetivo del estudio:

  • Resumir las guías actualizadas de diagnóstico y manejo para la enfermedad de Kawasaki.
  • Destacar las prácticas clave para el manejo de la enfermedad de Kawasaki en la Suiza francófona.
  • Analizar los avances en el tratamiento de casos refractarios y la prevención de complicaciones coronarias.

Principales métodos:

  • Revisión de las guías actuales europeas y norteamericanas para la enfermedad de Kawasaki.
  • Análisis de los criterios de diagnóstico basados en síntomas clínicos y duración de la fiebre.
  • Evaluación de los criterios coronarios de alto riesgo para guiar las decisiones de tratamiento temprano.

Principales resultados:

  • El diagnóstico se basa en una combinación de síntomas clínicos (cutáneos, mucosos, linfoides) dentro de los 4 días posteriores al inicio de la fiebre para las formas completas.
  • Los criterios coronarios de alto riesgo son cruciales para iniciar un tratamiento rápido.
  • Los avances en inmunoterapia y atención cardíaca han mejorado el pronóstico para la enfermedad refractaria y las complicaciones coronarias.

Conclusiones:

  • El diagnóstico y tratamiento tempranos, guiados por criterios actualizados, son esenciales para prevenir anomalías de las arterias coronarias en la enfermedad de Kawasaki.
  • Las estrategias de tratamiento actuales, incluidas las terapias inmunomoduladoras y cardíacas, ofrecen mejores resultados para casos complejos.
  • La adherencia a las guías actualizadas y las prácticas localizadas es clave para la atención óptima del paciente en la Suiza francófona.